FILING ANALYSIS · THURSDAY, NOVEMBER 5
NOVAVAX INC NVAX — 8-K: Results of Operations and Financial Condition
positive
Novavax reported a $125 million milestone payment from Sanofi and raised its full-year 2026 non-GAAP adjusted total revenue guidance to $400 million, driven by strong partner activities and a growing pipeline, including a differentiated C. difficile vaccine program and multiple experiments with Matrix-M in infectious disease and oncology targets.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →